The following changes have been decided in responsibility areas of the Orion Group Executive Management Board:
As of 1 October, 2018:
Mr. Markku Huhta-Koivisto, Senior Vice President, Proprietary Products business division will take the responsibility for projects aiming at the Orion Group's growth, as Senior Vice President, Growth Projects. Huhta-Koivisto's area of responsibility is a new one in the Orion Group.
Ms. Satu Ahomäki, Senior Vice President, Global Sales will, in addition to her current area of responsibility (sales of human pharmaceuticals), take the responsibility for Proprietary Products business division. The responsibility area of Ms. Ahomäki will be named as Commercial Operations.
As of 1 January, 2019:
Dr. Liisa Hurme, Senior Vice President, Specialty Products and Fermion will take the responsibility for Supply Chain line function. In addition, Fermion business division will still belong to Dr. Hurme's responsibility area.
Ms. Virve Laitinen, Senior Vice President, Supply Chain will take the responsibility for Specialty Products business division.
President and CEO, Chairman of the Orion Executive Management Board Mr. Timo Lappalainen says:
"I am pleased that we can further develop the Executive Management Board's operations through the exchanges of responsibility areas. Markku's new responsibility area reflects in its part our aspiration to accelerate growth of the Group. I also believe that the changes in responsibility areas of Satu, Liisa and Virve will have positive effects on the successful development of the Company."
| Timo Lappalainen |
President and CEO
| Olli Huotari |
SVP, Corporate Functions
Timo Lappalainen, President and CEO
Phone: +358 50 966 3692
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,034 million and the company had about 3,200 employees. Orion's A and B shares are listed on Nasdaq Helsinki.